论文部分内容阅读
常染色体显性多囊肾病能够缓慢进展到终末期肾脏病,目前没有有效的治疗方法。初步试验表明,生长抑素类似物奥曲肽缓释剂对常染色体显性多囊肾病可能具有治疗保护作用。因此,意大利学者对奥曲肽缓释剂治疗肾和囊肿生长以及肾功能下降的3年疗效进行了研究。研究者在意大利的五家医院进行了一项多中心、随机、单盲、安慰剂对照的平行组试验研究。对成人(>18岁)患者并且(2),:
Autosomal dominant polycystic kidney disease can progress slowly to end-stage renal disease, there is no effective treatment. Preliminary tests show that the somatostatin analogue octreotide sustained-release agent may have therapeutic protection on autosomal dominant polycystic kidney disease. Therefore, the Italian scholar on the octreotide sustained-release agent for the treatment of kidney and cyst growth and renal function decline of 3 years were studied. The researchers conducted a multicenter, randomized, single-blind, placebo-controlled, parallel-group study in five Italian hospitals. For adults (> 18 years) patients and (2) ,: